Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial.

Name: Kaimen Rigor review — Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial.
Item: Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial.
Rating: 96
Author: Alpha1

Perreault L, Pan Q, Rodriguez C, Gritz RM, Smith PC, Kramer ES, Tolle L, Connelly L, Tietbohl C, Williams J 2nd, Holtrop JS

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 1.5★ (Critical), 0 critical, 3 high issues for “Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial.

Perreault L, Pan Q, Rodriguez C, Gritz RM, Smith PC, Kramer ES, Tolle L, Connelly L, Tietbohl C, Williams J 2nd, Holtrop JS

Read full text (PMC)

DOI

10.1038/s41591-025-04051-5

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/b078cdc8-0252-4b2c-9284-ce04c7f5f591" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/b078cdc8-0252-4b2c-9284-ce04c7f5f591/badge" alt="Kaimen Rigor review — 1.5★ (Critical), 0 critical, 3 high issues for “Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

7b81326fb34c6221e1bfdbc73df40faabead01cd9d1508467a25b21388dd872c

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial.

Perreault L, Pan Q, Rodriguez C, Gritz RM, Smith PC, Kramer ES, Tolle L, Connelly L, Tietbohl C, Williams J 2nd, Holtrop JS

Paper source

Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

1.5 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on weight change, which is a surrogate endpoint for clinical outcomes such as mortality or cardiovascular events. The paper does not demonstrate target engagement at the tested dose (since it's a care process, not a drug) nor does it cite validated evidence linking weight loss to hard clinical outcomes in this context. The effect size is small (0.58 kg) and the paper itself notes it is not clinically meaningful for individual patients.
“This result should not be misinterpreted to mean that 0.58 kg is clinically meaningful to a singular patient; rather, it is urged to look beyond to its potential impact on public health.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary reported effect is a total difference of 0.58 kg over 18 months, which is a small fraction of typical body weight and below established minimal clinically important differences for weight loss (usually 5% or 5 kg). The paper acknowledges this is not clinically meaningful for individual patients, and no anchor to clinical meaningfulness is provided.
“This result should not be misinterpreted to mean that 0.58 kg is clinically meaningful to a singular patient; rather, it is urged to look beyond to its potential impact on public health.”
Find in source
03Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Trial NCT04678752 was first submitted to ClinicalTrials.gov on 2020-11-24, after the registered study start date of 2020-03-17. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT04678752
reviewer’s wording

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 103AuthenticityData authenticity concerns 104DisclosureReporting gaps 105AvailabilityBroken references and links 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported stepped-wedge cluster-randomized pragmatic trial. The main methodological strengths are the rigorous cluster randomization, detailed statistical methods, and comprehensive reporting of demographics and outcomes. The primary weakness is the vague data availability statement and lack of code sharing, which limits reproducibility.

Both reviewers agreed on all dimensions; no divergence to reconcile. The statistics verification covered only 3 tests (those with test statistics/df or effect+CI), so the paper's statistics are not fully verified. The citation check found 1 reference not found in any registry, which is a potential fabrication signal. The integrity check noted retrospective trial registration and minor internal rounding discrepancies.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 2 via agent-written checks.

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

5 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst medium

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

4 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites multiple references on obesity prevalence, barriers to weight management in clinical settings, and prior primary care weight loss trials. It acknowledges limitations of prior work (e.g., highly controlled trials not representative of routine practice) and explains how the pragmatic design addresses these gaps. The hypothesis follows logically from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the intervention.

Evidence

“Obesity has been recognized as a major health issue in Westernized countries for more than three decades.”

Introduction ¶1Find in source

“By randomizing on the clinic (versus patient) level, as was done in previous trials, only 6.3% of our patients were exposed to the types of interventions tested in highly controlled trials; hence, the results cannot be directly compared.”

Discussion ¶3Find in source

“Our objective was to determine whether the implementation of PATHWEIGH had greater effectiveness on patient weight loss and weight maintenance compared with usual care.”

Introduction ¶2Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale linking obesity burden to the need for scalable primary care interventions.

Evidence

“Obesity has been recognized as a major health issue in Westernized countries for more than three decades.”

Introduction ¶1Find in source

“Our objective was to determine whether the implementation of PATHWEIGH had greater effectiveness on patient weight loss and weight maintenance compared with usual care.”

Introduction ¶2Find in source

“Interventions tested in primary care, specifically, have shown successful patient weight loss under conditions in which patients have been recruited into a weight loss intervention with a set curriculum and coaches – , neither of which are reminiscent of routine practice.”

Discussion ¶2Find in source

Randomization was performed at the clinic level using computer-generated covariate-constrained randomization, with the method and unit clearly stated. Blinding is described (clinics unaware of sequence assignment until 3 months before implementation). The trial is registered and the protocol published. Inclusion/exclusion criteria are prespecified. Power analysis is not explicitly reported, but the large sample size and pragmatic design make it less critical; however, this is a minor gap. Outlier handling is described (BMI exclusions). Controls are inherent in the stepped-wedge design (usual care phase). Independent replication is not applicable for a single pragmatic trial.

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The stepped-wedge cluster-randomized design is well-described with adequate randomization, blinding, and prespecified analyses.

Evidence

paraphrase[Methods, Trial design]

“Clinics were randomized into three clusters using computer-generated covariate-constrained randomization balanced for patient volume, percentage of patients on Medicaid, academic versus nonacademic, practice type (family medicine, internal medicine or both) and geographical location of the clinic (rural versus urban or suburban).”

paraphrase[Methods, Trial design]

“All clinics were unaware of their randomized sequence assignment until 3 months before the implementation of the intervention.”

“The ITT population under study was composed of adults (≥ 18 years) having a BMI ≥ 25 kg m 2 and were seen and weighed in one of the clinics by a primary care clinician with a national provider identifier between 17 March 2020 and 16 March 2024.”

MethodsFind in source

PASSReviewer 2· 95% conf

The stepped-wedge cluster-randomized design is well-described with adequate randomization, blinding, and prespecified analyses.

Evidence

paraphrase[Methods, Trial design]

“All clinics were unaware of their randomized sequence assignment until 3 months before the implementation of the intervention.”

MethodsFind in source

Sex, age, race/ethnicity, insurance, weight, BMI, blood pressure, labs, and comorbidities are reported in Table 1. Both sexes are included, so sex justification is not applicable. Age and health status are reported. Species/strain and housing are not applicable for a human trial. Demographics are well-covered.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and health metrics are comprehensively reported for the study population.

Evidence

paraphrase[Table 1]

“Sex | Female | 51,692 (50.1%) | 18,699 (52.7%) | 34,140 (51.7%) | 27,293 (61.7%) | 3,673 (58.6%) | 11,580 (61.3%)”

“Age (years) | 56.1 (17.2) | 51.5 (18.7) | 50.5 (18.0) | 52.8 (15.4) | 47.9 (15.8) | 49.0 (15.7)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and health metrics are comprehensively reported for the study population.

Evidence

“Female | 51,692 (50.1%) | 18,699 (52.7%) | 34,140 (51.7%) | 27,293 (61.7%) | 3,673 (58.6%) | 11,580 (61.3%)”

Table 1Find in source

“Age (years) | 56.1 (17.2) | 51.5 (18.7) | 50.5 (18.0) | 52.8 (15.4) | 47.9 (15.8) | 49.0 (15.7)”

Table 1Find in source

“The demographics and health metrics of patients included in this analysis are shown in Table and are highly representative of the demographics of adults residing in Colorado.”

ResultsFind in source

The study was approved by the Colorado Multiple Institutional Review Board, and a waiver of informed consent was granted because data were de-identified. This satisfies both IRB approval and informed consent handling. Regulatory compliance is implied by IRB approval, though not explicitly named; however, the IRB approval is sufficient.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and waiver of informed consent are clearly documented.

Evidence

paraphrase[Methods, Trial population]

“Because all data were de-identified, the study was exempt from informed consent and approved by the Colorado Multiple Institutional Review Board, including a waiver of informed consent, and the full protocol has been published.”

PASSReviewer 2· 95% conf

Ethical approval and waiver of informed consent are clearly documented.

Evidence

MethodsFind in source

The intervention components are thoroughly described, including EHR customization and implementation strategies. No drugs or devices are used as investigational products; the intervention is a care process. Software (R version, packages) is identified. Antibodies, cell lines, mycoplasma, and organisms are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedN/A

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (PATHWEIGH intervention) is described in detail, and software tools are identified.

Evidence

“Data were collected using R v.4.4.1. Data analysis used R ImerTest 3.1-3 for the main modeling and Ime 4 1.1-35.5 for contrasts and confidence intervals.”

Statistical analysisFind in source

paraphrase[Methods, Trial intervention]

“The trial intervention included a bundle of three components. Health system primary care leadership endorsement. Implementation strategies. Customization of the EHR.”

PASSReviewer 2· 85% conf

The intervention is described in detail, and software tools are identified; no biological reagents are used.

Evidence

“Data were collected using R v.4.4.1. Data analysis used R ImerTest 3.1-3 for the main modeling and Ime 4 1.1-35.5 for contrasts and confidence intervals.”

Statistical analysisFind in source

“Customization of the EHR was one component of PATHWEIGH and included three sequential steps for patients, clinic staff and clinicians.”

MethodsFind in source

Tests are named (linear mixed models, GEE logistic models, chi-square tests). Assumptions are addressed through model selection and sensitivity analyses. Exact p-values are reported throughout. Effect sizes with confidence intervals are provided. Software is identified. Data presentation includes figures and tables with per-group n. Mathematical plausibility checks: the reported percentages and counts appear consistent; no obvious arithmetic errors detected.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityPASS

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals reported.

Evidence

“PATHWEIGH decreased average weight by 0.29 kg (95% confidence interval (CI): 0.27 kg, 0.32 kg) from the first weight to 6 months later ( P < 0.001)”

AbstractFind in source

“Linear mixed models were used to analyze patient weight trajectories from the index weight to all other weight measures in the usual care and intervention phases.”

Statistical analysisFind in source

“Data were collected using R v.4.4.1. Data analysis used R ImerTest 3.1-3 for the main modeling and Ime 4 1.1-35.5 for contrasts and confidence intervals.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals reported.

Evidence

“Linear mixed models were used to analyze patient weight trajectories from the index weight to all other weight measures in the usual care and intervention phases.”

Statistical analysisFind in source

“PATHWEIGH decreased average weight by 0.29 kg (95% confidence interval (CI): 0.27 kg, 0.32 kg) from the first weight to 6 months later ( P < 0.001)”

AbstractFind in source

“A sensitivity analysis comparing the 3-piecewise linear model (presented herein) to more flexible models using 8 or 19 pieces is provided in Extended Data Table .”

LimitationsFind in source

The data availability statement says 'De-identified data may be shared upon request' without specifying a mechanism, conditions, or timeframe, which is inadequate per the criteria. No repository deposit or accession numbers are provided. No code sharing is mentioned. Since the study involves patient data, repository deposit and accession numbers are not applicable, but the data availability statement should be more concrete.

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 90% conf

A data availability statement exists but is vague, and no code is shared.

Evidence

“De-identified data may be shared upon request.”

Data availabilityFind in source

absence[Data availability]

No code sharing is mentioned.

WARNReviewer 2· 90% conf

A data availability statement exists but is vague, offering data 'upon request' without a clear mechanism or conditions.

Evidence

“De-identified data may be shared upon request.”

Data availabilityFind in source

absence[Data availability]

No code sharing is mentioned.

The trial is registered (NCT04678752). Methods are detailed enough for replication. A reporting summary is mentioned. All outcomes are reported, including null results. Limitations are thoroughly discussed. Conclusions are proportional to the evidence. Funding and competing interests are stated.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with trial registration, detailed methods, and discussion of limitations.

Evidence

“ClinicalTrials.gov registration: NCT04678752”

AbstractFind in source

“Results from this pragmatic trial should be interpreted in light of its limitations.”

Discussion ¶6Find in source

“This work was funded by the National Institutes of Health (1R18DK127003).”

AcknowledgementsFind in source

PASSReviewer 2· 95% conf

The manuscript is transparent, with trial registration, detailed methods, limitations, and funding/COI statements.

Evidence

“ClinicalTrials.gov registration: NCT04678752”

AbstractFind in source

“Results from this pragmatic trial should be interpreted in light of its limitations.”

LimitationsFind in source

“This work was funded by the National Institutes of Health (1R18DK127003).”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 29 references by DOI: 0 verified — 1 DOI unresolved, 28 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust in design and reporting, but readers should weigh the retrospective trial registration and the vague data/code availability as limitations. The minor internal inconsistencies (rounding, CI notation) and the unresolved reference warrant attention but do not undermine the main conclusions.

1.
HIGHdata code
Replace the vague data availability statement in the Data Availability section with a concrete managed-access plan, specifying a platform (e.g., Vivli) or a data access committee with conditions and a timeframe.
The current 'upon request' statement is inadequate for reproducibility and does not meet the standard for patient-level data sharing.
2.
HIGHdata code
Share the custom data processing and analysis pipeline code in a public repository (e.g., GitHub or Zenodo) with a DOI, and link it in the Data Availability section.
Releasing code enhances reproducibility and is expected for a data-driven pragmatic trial.
3.
HIGHreporting
Verify and correct the reference 'Obesity and severe obesity prevalence in adults: United States, August 2021–August 2023' (DOI 10.1016/s0140-6736(25) — it was not found in any registry and may be fabricated or have an incomplete DOI.
An unresolved reference is a fabrication signal that must be resolved before publication.
4.
MEDIUMreporting
Add a power analysis or sample size justification in the Methods, even if post hoc, to strengthen the study design reporting.
The absence of a power analysis is a minor gap that reviewers may question.
5.
MEDIUMreporting
Explicitly state adherence to CONSORT guidelines and provide the CONSORT checklist as supplementary material.
While the paper follows CONSORT-like flow, explicit adherence improves transparency and reviewer confidence.
6.
MEDIUMreporting
Clarify the retrospective registration of the trial (NCT04678752) in the manuscript, noting the registration date relative to the study start, and discuss any implications.
Retrospective registration is a transparency concern that readers should be aware of.
7.
MEDIUMstatistics
Correct the CI notation in the Results section for the chi-square tests (e.g., '95% CI (5.9%, 4.9%)') to clearly indicate it is a difference in proportions with a proper CI format.
The current notation is confusing and may mislead readers.
8.
MEDIUMcopyedit
Fix the inconsistent p-value formatting in the Results section (e.g., 'P = .007' to 'P = 0.007') and ensure leading zeros are used consistently.
Consistent formatting is expected in a professional manuscript.
9.
MEDIUMcopyedit
Correct the BMI unit formatting in the Abstract from 'kg m 2' to 'kg m−2'.
Proper superscript formatting is required for scientific accuracy.
10.
MEDIUMreporting
Verify the reported average time in the intervention phase (32 months) for patients receiving weight-related care, as it seems inconsistent with the study period (March 2020–March 2024) and staggered rollout.
An implausible duration could indicate an error in the analysis or reporting.
11.
LOWreporting
Clarify the minor rounding discrepancy between the abstract's total difference (0.58 kg) and the results section (0.47 kg gain + 0.10 kg loss = 0.57 kg).
Rounding discrepancies can be easily corrected to avoid confusion.
12.
LOWreporting
Clarify the role of the 'reporting summary' mentioned in the paper and ensure it is accessible to readers.
Transparency about reporting checklists is important for reproducibility.

Full text (48,673 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial.

Perreault L, Pan Q, Rodriguez C, Gritz RM, Smith PC, Kramer ES, Tolle L, Connelly L, Tietbohl C, Williams J 2nd, Holtrop JS

Read full text (PMC)

DOI

10.1038/s41591-025-04051-5

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/b078cdc8-0252-4b2c-9284-ce04c7f5f591" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/b078cdc8-0252-4b2c-9284-ce04c7f5f591/badge" alt="Kaimen Rigor review — 1.5★ (Critical), 0 critical, 3 high issues for “Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

7b81326fb34c6221e1bfdbc73df40faabead01cd9d1508467a25b21388dd872c

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

1.5 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on weight change, which is a surrogate endpoint for clinical outcomes such as mortality or cardiovascular events. The paper does not demonstrate target engagement at the tested dose (since it's a care process, not a drug) nor does it cite validated evidence linking weight loss to hard clinical outcomes in this context. The effect size is small (0.58 kg) and the paper itself notes it is not clinically meaningful for individual patients.
“This result should not be misinterpreted to mean that 0.58 kg is clinically meaningful to a singular patient; rather, it is urged to look beyond to its potential impact on public health.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary reported effect is a total difference of 0.58 kg over 18 months, which is a small fraction of typical body weight and below established minimal clinically important differences for weight loss (usually 5% or 5 kg). The paper acknowledges this is not clinically meaningful for individual patients, and no anchor to clinical meaningfulness is provided.
“This result should not be misinterpreted to mean that 0.58 kg is clinically meaningful to a singular patient; rather, it is urged to look beyond to its potential impact on public health.”
Find in source
03Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Trial NCT04678752 was first submitted to ClinicalTrials.gov on 2020-11-24, after the registered study start date of 2020-03-17. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT04678752
reviewer’s wording

Findings by category

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 3 tests: 3 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 2 via agent-written checks.

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

5 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst medium

Other integrity concernAssessed

4 integrity concerns flagged (0 high).

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the intervention.

Evidence

“Obesity has been recognized as a major health issue in Westernized countries for more than three decades.”

Introduction ¶1Find in source

Discussion ¶3Find in source

“Our objective was to determine whether the implementation of PATHWEIGH had greater effectiveness on patient weight loss and weight maintenance compared with usual care.”

Introduction ¶2Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale linking obesity burden to the need for scalable primary care interventions.

Evidence

“Obesity has been recognized as a major health issue in Westernized countries for more than three decades.”

Introduction ¶1Find in source

“Our objective was to determine whether the implementation of PATHWEIGH had greater effectiveness on patient weight loss and weight maintenance compared with usual care.”

Introduction ¶2Find in source

Discussion ¶2Find in source

Sub-criteria

controlsADEQUATE

power analysisNOT REPORTED

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The stepped-wedge cluster-randomized design is well-described with adequate randomization, blinding, and prespecified analyses.

Evidence

paraphrase[Methods, Trial design]

“All clinics were unaware of their randomized sequence assignment until 3 months before the implementation of the intervention.”

MethodsFind in source

PASSReviewer 2· 95% conf

The stepped-wedge cluster-randomized design is well-described with adequate randomization, blinding, and prespecified analyses.

Evidence

paraphrase[Methods, Trial design]

“All clinics were unaware of their randomized sequence assignment until 3 months before the implementation of the intervention.”

MethodsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and health metrics are comprehensively reported for the study population.

Evidence

paraphrase[Table 1]

“Sex | Female | 51,692 (50.1%) | 18,699 (52.7%) | 34,140 (51.7%) | 27,293 (61.7%) | 3,673 (58.6%) | 11,580 (61.3%)”

“Age (years) | 56.1 (17.2) | 51.5 (18.7) | 50.5 (18.0) | 52.8 (15.4) | 47.9 (15.8) | 49.0 (15.7)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and health metrics are comprehensively reported for the study population.

Evidence

“Female | 51,692 (50.1%) | 18,699 (52.7%) | 34,140 (51.7%) | 27,293 (61.7%) | 3,673 (58.6%) | 11,580 (61.3%)”

Table 1Find in source

“Age (years) | 56.1 (17.2) | 51.5 (18.7) | 50.5 (18.0) | 52.8 (15.4) | 47.9 (15.8) | 49.0 (15.7)”

Table 1Find in source

“The demographics and health metrics of patients included in this analysis are shown in Table and are highly representative of the demographics of adults residing in Colorado.”

ResultsFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and waiver of informed consent are clearly documented.

Evidence

paraphrase[Methods, Trial population]

PASSReviewer 2· 95% conf

Ethical approval and waiver of informed consent are clearly documented.

Evidence

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedN/A

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (PATHWEIGH intervention) is described in detail, and software tools are identified.

Evidence

“Data were collected using R v.4.4.1. Data analysis used R ImerTest 3.1-3 for the main modeling and Ime 4 1.1-35.5 for contrasts and confidence intervals.”

Statistical analysisFind in source

paraphrase[Methods, Trial intervention]

“The trial intervention included a bundle of three components. Health system primary care leadership endorsement. Implementation strategies. Customization of the EHR.”

PASSReviewer 2· 85% conf

The intervention is described in detail, and software tools are identified; no biological reagents are used.

Evidence

“Data were collected using R v.4.4.1. Data analysis used R ImerTest 3.1-3 for the main modeling and Ime 4 1.1-35.5 for contrasts and confidence intervals.”

Statistical analysisFind in source

“Customization of the EHR was one component of PATHWEIGH and included three sequential steps for patients, clinic staff and clinicians.”

MethodsFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityPASS

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals reported.

Evidence

“PATHWEIGH decreased average weight by 0.29 kg (95% confidence interval (CI): 0.27 kg, 0.32 kg) from the first weight to 6 months later ( P < 0.001)”

AbstractFind in source

“Linear mixed models were used to analyze patient weight trajectories from the index weight to all other weight measures in the usual care and intervention phases.”

Statistical analysisFind in source

“Data were collected using R v.4.4.1. Data analysis used R ImerTest 3.1-3 for the main modeling and Ime 4 1.1-35.5 for contrasts and confidence intervals.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and confidence intervals reported.

Evidence

“Linear mixed models were used to analyze patient weight trajectories from the index weight to all other weight measures in the usual care and intervention phases.”

Statistical analysisFind in source

“PATHWEIGH decreased average weight by 0.29 kg (95% confidence interval (CI): 0.27 kg, 0.32 kg) from the first weight to 6 months later ( P < 0.001)”

AbstractFind in source

“A sensitivity analysis comparing the 3-piecewise linear model (presented herein) to more flexible models using 8 or 19 pieces is provided in Extended Data Table .”

LimitationsFind in source

Sub-criteria

code sharingNOT REPORTED

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 90% conf

A data availability statement exists but is vague, and no code is shared.

Evidence

“De-identified data may be shared upon request.”

Data availabilityFind in source

absence[Data availability]

No code sharing is mentioned.

WARNReviewer 2· 90% conf

A data availability statement exists but is vague, offering data 'upon request' without a clear mechanism or conditions.

Evidence

“De-identified data may be shared upon request.”

Data availabilityFind in source

absence[Data availability]

No code sharing is mentioned.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The manuscript is transparent with trial registration, detailed methods, and discussion of limitations.

Evidence

“ClinicalTrials.gov registration: NCT04678752”

AbstractFind in source

“Results from this pragmatic trial should be interpreted in light of its limitations.”

Discussion ¶6Find in source

“This work was funded by the National Institutes of Health (1R18DK127003).”

AcknowledgementsFind in source

PASSReviewer 2· 95% conf

The manuscript is transparent, with trial registration, detailed methods, limitations, and funding/COI statements.

Evidence

“ClinicalTrials.gov registration: NCT04678752”

AbstractFind in source

“Results from this pragmatic trial should be interpreted in light of its limitations.”

LimitationsFind in source

“This work was funded by the National Institutes of Health (1R18DK127003).”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 29 references by DOI: 0 verified — 1 DOI unresolved, 28 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
Replace the vague data availability statement in the Data Availability section with a concrete managed-access plan, specifying a platform (e.g., Vivli) or a data access committee with conditions and a timeframe.
The current 'upon request' statement is inadequate for reproducibility and does not meet the standard for patient-level data sharing.
2.
HIGHdata code
Share the custom data processing and analysis pipeline code in a public repository (e.g., GitHub or Zenodo) with a DOI, and link it in the Data Availability section.
Releasing code enhances reproducibility and is expected for a data-driven pragmatic trial.
3.
HIGHreporting
Verify and correct the reference 'Obesity and severe obesity prevalence in adults: United States, August 2021–August 2023' (DOI 10.1016/s0140-6736(25) — it was not found in any registry and may be fabricated or have an incomplete DOI.
An unresolved reference is a fabrication signal that must be resolved before publication.
4.
MEDIUMreporting
Add a power analysis or sample size justification in the Methods, even if post hoc, to strengthen the study design reporting.
The absence of a power analysis is a minor gap that reviewers may question.
5.
MEDIUMreporting
Explicitly state adherence to CONSORT guidelines and provide the CONSORT checklist as supplementary material.
While the paper follows CONSORT-like flow, explicit adherence improves transparency and reviewer confidence.
6.
MEDIUMreporting
Clarify the retrospective registration of the trial (NCT04678752) in the manuscript, noting the registration date relative to the study start, and discuss any implications.
Retrospective registration is a transparency concern that readers should be aware of.
7.
MEDIUMstatistics
Correct the CI notation in the Results section for the chi-square tests (e.g., '95% CI (5.9%, 4.9%)') to clearly indicate it is a difference in proportions with a proper CI format.
The current notation is confusing and may mislead readers.
8.
MEDIUMcopyedit
Fix the inconsistent p-value formatting in the Results section (e.g., 'P = .007' to 'P = 0.007') and ensure leading zeros are used consistently.
Consistent formatting is expected in a professional manuscript.
9.
MEDIUMcopyedit
Correct the BMI unit formatting in the Abstract from 'kg m 2' to 'kg m−2'.
Proper superscript formatting is required for scientific accuracy.
10.
MEDIUMreporting
Verify the reported average time in the intervention phase (32 months) for patients receiving weight-related care, as it seems inconsistent with the study period (March 2020–March 2024) and staggered rollout.
An implausible duration could indicate an error in the analysis or reporting.
11.
LOWreporting
Clarify the minor rounding discrepancy between the abstract's total difference (0.58 kg) and the results section (0.47 kg gain + 0.10 kg loss = 0.57 kg).
Rounding discrepancies can be easily corrected to avoid confusion.
12.
LOWreporting
Clarify the role of the 'reporting summary' mentioned in the paper and ensure it is accessible to readers.
Transparency about reporting checklists is important for reproducibility.

Full text (48,673 chars)Analyzed: Aug 15, 2026